Peptide Nucleic Acid as Therapeutic Agent


With a repeating N-(2-aminoethyl)-glycine peptide backbone coupled to purine and pyrimidine nucleobases via a linker, PNA are synthetic analogues of DNA. PNA-based technology has received a lot of interest as a viable method for gene modification due to the unique qualities of PNA, including resistance to enzymatic digestion, increased bio stability, and excellent hybridization affinity toward DNA and RNA. However, inadequate intracellular absorption presents a significant obstacle to the use of PNA. To improve PNA delivery and ensure that it reaches the appropriate spot, some solutions have been devised


    Related Conference of Peptide Nucleic Acid as Therapeutic Agent

    May 04-05, 2026

    7th International Conference on Drug Chemistry

    Paris, France
    September 03-04, 2026

    16th World Glycobiology Congress

    Aix-en-Provence, France
    September 21-22, 2026

    24th International Conference on Structural Biology

    A Coruna, Spain

    Peptide Nucleic Acid as Therapeutic Agent Conference Speakers